1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Generics in Scandinavia

Generics in Scandinavia

  • January 2017
  • -
  • MarketLine
  • -
  • 32 pages

Summary
Generics in Scandinavia industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Findings
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Scandinavia
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Scandinavia
- Leading company profiles reveal details of key generics market players' global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Scandinavia generics market with five year forecasts by both value and volume

Synopsis
Essential resource for top-line data and analysis covering the Scandinavia generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Reasons To Buy
- What was the size of the Scandinavia generics market by value in 2016?
- What will be the size of the Scandinavia generics market in 2021?
- What factors are affecting the strength of competition in the Scandinavia generics market?
- How has the market performed over the last five years?
- How large is Scandinavia's generics market in relation to its regional counterparts?

Key Findings
For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

The Scandinavian generics market is expected to generate total revenues of $2.5bn in 2016, representing a compound annual growth rate (CAGR) of 4.6% between 2012 and 2016.

Market consumption volume is forecast to decline with a compound annual rate of change (CARC) of -2.8% between 2012 and 2016, to reach a total of 47.8% of total pharma volume in 2016.

Denmark has some of the lowest prices on generics in Europe; they are around 86% lower than Norwegian prices and 12% lower than Swedish prices. Generic drugs represent a saving of DKK1bn compared to Norway and DKK750m compared to Sweden.

Table Of Contents

Generics in Scandinavia
Table of Contents
Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Mylan Inc.
Sandoz International GmbH
Sanofi SA
Teva Pharmaceutical Industries Limited
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

List of Tables
Table 1: Scandinavia generics market value: $ billion, 2012-16(e)
Table 2: Scandinavia generics market volume: % of total pharma volume, 2012-16(e)
Table 3: Scandinavia generics market geography segmentation: $ billion, 2016(e)
Table 4: Scandinavia generics market value forecast: $ billion, 2016-21
Table 5: Scandinavia generics market volume forecast: % of total pharma volume, 2016-21
Table 6: Mylan Inc.: key facts
Table 7: Mylan Inc.: key financials ($)
Table 8: Mylan Inc.: key financial ratios
Table 9: Sandoz International GmbH: key facts
Table 10: Sanofi SA: key facts
Table 11: Sanofi SA: key financials ($)
Table 12: Sanofi SA: key financials (€)
Table 13: Sanofi SA: key financial ratios
Table 14: Teva Pharmaceutical Industries Limited: key facts
Table 15: Teva Pharmaceutical Industries Limited: key financials ($)
Table 16: Teva Pharmaceutical Industries Limited: key financial ratios

List of Figures
Figure 1: Scandinavia generics market value: $ billion, 2012-16(e)
Figure 2: Scandinavia generics market volume: % of total pharma volume, 2012-16(e)
Figure 3: Scandinavia generics market geography segmentation: % share, by value, 2016(e)
Figure 4: Scandinavia generics market value forecast: $ billion, 2016-21
Figure 5: Scandinavia generics market volume forecast: % of total pharma volume, 2016-21
Figure 6: Forces driving competition in the generics market in Scandinavia, 2016
Figure 7: Drivers of buyer power in the generics market in Scandinavia, 2016
Figure 8: Drivers of supplier power in the generics market in Scandinavia, 2016
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Scandinavia, 2016
Figure 10: Factors influencing the threat of substitutes in the generics market in Scandinavia, 2016
Figure 11: Drivers of degree of rivalry in the generics market in Scandinavia, 2016
Figure 12: Mylan Inc.: revenues and profitability
Figure 13: Mylan Inc.: assets and liabilities
Figure 14: Sanofi SA: revenues and profitability
Figure 15: Sanofi SA: assets and liabilities
Figure 16: Teva Pharmaceutical Industries Limited: revenues and profitability
Figure 17: Teva Pharmaceutical Industries Limited: assets and liabilities

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025 Summary Psoriatic arthritis (PsA) is a chronic immune-mediated arthritis typically affecting the large joints, especially ...

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.